Clinical trial of a probiotic and herbal supplement for lung health.
Clinical trial of a probiotic and herbal supplement for lung health.
复制标题
益生菌和草药补充剂对肺部健康的临床试验。
DOI：
10.3389/fnut.2023.1168582
复制
发表时间：
2023
影响因子：
5
通讯作者：
Lal, Charitharth Vivek
中科院分区：
文献类型：
--
作者：
Wenger, Nancy M.;Qiao, Luhua;Nicola, Teodora;Nizami, Zoha;Martin, Isaac;Halloran, Brian A.;Tanaka, Kosuke;Evans, Michael;Xu, Xin;Dinan, Timothy G.;Kakilla, Charles;DunnGalvin, Gillian;Ambalavanan, Namasivayam;Willis, Kent A.;Gaggar, Amit;Lal, Charitharth Vivek
肠道微生物群的失调可能通过肠道-肺轴加重肺部疾病。变形杆菌可能导致组织蛋白分解，随后中性粒细胞重新聚集，肺组织损伤，以及慢性炎症的持续。为了研究益生菌对肠道-肺轴的影响，我们试图确定乳杆菌益生菌和草药混合物在健康志愿者和哮喘患者中是否安全和耐受性良好。我们在爱尔兰科克进行了为期1个月的随机开放标签临床试验，对象为健康和哮喘患者，他们每天服用两次这种混合物。主要终点是安全性，探索性终点包括生活质量、肺功能、肠道微生物生态和炎症生物标志物。所有受试者都能耐受这种混合物，没有不良反应。从基线到第4周，服用混合制剂的哮喘患者的肺功能有了显著的改善，通过测量用力呼气容量和血清短链脂肪酸水平。哮喘患者的肠道微生物群与对照组有显著差异，其中最显著的是变形杆菌大肠杆菌的相对丰度。给予益生菌维持了整个微生物群落结构，唯一显着的差异是通过菌株特异性PCR测量的益生菌菌株的绝对丰度增加。这项研究支持乳杆菌益生菌和草药混合物作用于肠道-肺轴的安全性和有效性。然而，由于缺乏对照组，将需要一项更长时间的盲法、安慰剂对照研究来证实在这项试验中观察到的疗效改善。Https://clinicaltrials.gov/，标识符NCT05173168。
Dysbiosis of the gut microbiome may augment lung disease via the gut-lung axis. Proteobacteria may contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic inflammation. To study the effects of probiotics across the gut-lung axis, we sought to determine if a Lactobacillus probiotic and herbal blend was safe and well-tolerated in healthy volunteers and asthmatic patients. We conducted a 1-month randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took the blend twice a day. The primary endpoint was safety with exploratory endpoints including quality of life, lung function, gut microbiome ecology, and inflammatory biomarkers. All subjects tolerated the blend without adverse events. Asthmatic subjects who took the blend showed significant improvements in lung function as measured by forced expiratory volume and serum short chain fatty acid levels from baseline to Week 4. The gut microbiome of asthmatic subjects differed significantly from controls, with the most prominent difference in the relative abundance of the proteobacteria Escherichia coli. Administration of the probiotic maintained overall microbial community architecture with the only significant difference being an increase in absolute abundance of the probiotic strains measured by strain-specific PCR. This study supports the safety and efficacy potential of a Lactobacillus probiotic plus herbal blend to act on the gut-lung axis. However, due to the lack of a control group, a longer blinded, placebo-controlled study will be warranted to confirm the efficacy improvements observed in this trial. https://clinicaltrials.gov/, identifier NCT05173168.
登录
查看更多内容
影响因子：
14.2
作者：
Marri, Pradeep Reddy;Stern, Debra A.;Wright, Anne L.;Billheimer, Dean;Martinez, Fernando D.
通讯作者：
Martinez, Fernando D.
影响因子：
30.3
作者：
Liou, Megan J.;Miller, Brittany M.;Litvak, Yael;Nguyen, Henry;Natwick, Dean E.;Savage, Hannah P.;Rixon, Jordan A.;Mahan, Scott P.;Hiyoshi, Hirotaka;Rogers, Andrew W. L.;Velazquez, Eric M.;Butler, Brian P.;Collins, Sean R.;McSorley, Stephen J.;Harshey, Rasika M.;Byndloss, Mariana X.;Simon, Scott I.;Baumler, Andreas J.
通讯作者：
Baumler, Andreas J.
影响因子：
8
作者：
Cait, A.;Hughes, M. R.;Mohn, W. W.
通讯作者：
Mohn, W. W.
DOI：
10.34172/bi.2021.03
发表时间：
2021
期刊：
BioImpacts : BI
影响因子：
--
作者：
Amala R;Sujatha S
通讯作者：
Sujatha S
影响因子：
6.1
作者：
Maheshwari, RK;Singh, AK;Srimal, RC
通讯作者：
Srimal, RC